



Syndax Pharmaceuticals, Inc.  
Investor Relations Department  
35 Gatehouse Drive  
Building D, Floor 3  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: SNDX

Last Trade:	9.53
Trade Time:	2:27 PM ET 02.20.18
Change:	0.05 (+0.527%)
Day Range	9.22 - 9.82
52-Week Range	7.41 - 15.70
Volume	193,684

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 02.01.18  
[Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca](#)
- 01.10.18  
[Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer](#)
- 11.11.17  
[Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting](#)
- 11.07.17  
[Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update](#)
- 11.07.17  
[Syndax to Present at the SITC 32nd Annual Scientific Meeting](#)

## Financial Information [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- 03.14.17  
[Annual Report \(10-K\)](#)
- 04.07.17  
[Proxy Statement \(DEF 14A\)](#)
- 11.08.17  
[Quarterly Report \(10-Q\)](#)
- 08.10.17  
[Quarterly Report \(10-Q\)](#)
- 05.09.17  
[Quarterly Report \(10-Q\)](#)